KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
An Evaluation of the Effectiveness of Patient Navigation on Colonoscopy Screening Adherence for Colorectal Cancer: A Randomized Controlled Trial. PMID 41216654 · Asia Pac J Public Health · 2025-Nov The study is a Phase III RCT in oncology (colorectal cancer screening) with original results, but it is excluded because it lacks a drug-containing intervention and does not have a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial. PMID 41202503 · ESMO Open · 2025-Nov The record describes an unplanned exploratory analysis from the PHERGain trial. While the parent trial is likely a definitive Phase III RCT, this specific report is a secondary analysis focusing on imaging comparisons, not the primary report of the main trial's efficacy results. The phase of the parent trial is not explicitly confirmed in the provided metadata (e.g., publication types list 'Randomized Controlled Trial' but not 'Phase III'). Therefore, eligibility cannot be fully established without confirming the primary trial's phase and that this report constitutes the original primary result.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-Term Survival of Two Versus Three Courses of Preoperative Cisplatin and Fluorouracil Plus Docetaxel for Locally Advanced Esophageal Cancer: A Multicenter Randomized Phase II Trial. PMID 41199984 · Ann Gastroenterol Surg · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial (HiSCO-01). PMID 41199978 · Ann Gastroenterol Surg · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial. PMID 41194516 · Eur J Neurol · 2025-Nov 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. PMID 41193116 · Lancet Haematol · 2025-Nov While the study meets most inclusion criteria (oncology, human, randomized, Phase 3, drug intervention, original results), the primary efficacy endpoint is a response rate, not a time-to-event endpoint required for the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comment on 'A phase III randomized trial evaluating the quality of life impact of a tailored versus systematic use of defunctioning ileostomy following total mesorectal excision for rectal cancer-GRECCAR 17 trial protocol'. PMID 41186212 · Colorectal Dis · 2025-Nov 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Emotion and Symptom-Focused Engagement (EASE) Psychotherapeutic Intervention for Parents of Children With Acute Leukemia: A Feasibility Trial. PMID 41161769 · Psychooncology · 2025-Nov The study is a single-arm feasibility trial (non-randomized) evaluating a psychotherapeutic intervention for caregivers of children with leukemia. It is not a randomized drug trial and does not report time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Perioperative camrelizumab and apatinib combined with chemotherapy for locally advanced gastric cancer in China: three-year survival outcomes of phase 2 randomized controlled trial. PMID 41140456 · EClinicalMedicine · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma. PMID 41117344 · Hematol Oncol · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial. PMID 41075365 · ESMO Open · 2025-Nov The record describes a randomized, drug-interventional oncology trial with time-to-event endpoints, but the trial phase (III/IIIb or II/III) is not explicitly established in the provided metadata. Furthermore, the analysis presented is a secondary subgroup analysis (BMI modulation of TILs) rather than the primary report of the trial's main efficacy results. Therefore, eligibility cannot be definitively determined.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials. PMID 41071419 · Gastric Cancer · 2025-Nov The report is a health-related quality-of-life analysis from a Phase III randomized trial, which is excluded by the specified criteria despite containing drug intervention and time-to-event signals.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263). PMID 41056581 · Gynecol Oncol · 2025-Nov The study is an eligible randomized Phase III oncology trial with a drug intervention, but it reports patient-reported quality-of-life outcomes, not a formal time-to-event efficacy endpoint as required for inclusion in the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial. PMID 41033130 · Lung Cancer · 2025-Nov The study is a Phase 3B trial with a time-to-event efficacy endpoint (overall survival) and a drug-containing intervention. However, it is a single-arm, non-randomized study. The inclusion criteria require a randomized trial, so the record is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Response to comments on: intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open-label, phase II/III study. PMID 40999184 · Gastric Cancer · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. PMID 40993242 · Nat Med · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc. PMID 40968753 · J Gynecol Oncol · 2025-Nov Phase of trial is not explicitly stated in provided metadata; cannot confirm if Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma. PMID 40952913 · J Manag Care Spec Pharm · 2025-Nov The report is a cost-effectiveness analysis derived from the PERSEUS trial, focusing on economic outcomes (cost per MRD-negative patient). It does not present a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, or DFS with Kaplan-Meier estimates or hazard ratios. Therefore, it is excluded as a health-economic analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial. PMID 40946347 · J Diabetes Complications · 2025-Nov The study is a randomized controlled trial of a drug intervention in humans, but it is not an oncology study (focus is diabetic kidney disease) and lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The endpoints are biomarkers and renal function measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis. PMID 40939735 · Contemp Clin Trials · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Eligibility criteria in phase 3 randomized controlled trials in gastric cancer. PMID 40932583 · Gastric Cancer · 2025-Nov The publication is a methodological review/analysis of eligibility criteria across multiple phase 3 RCTs, not an original report of a single trial's results with a time-to-event primary/key secondary endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087). PMID 40930276 · Radiother Oncol · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. PMID 40929627 · J Clin Oncol · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study. PMID 40898993 · Phytother Res · 2025-Nov The record does not provide explicit evidence that the trial is Phase III/IIIb or Phase II/III. While it is a randomized, oncology trial with drug intervention and time-to-event endpoints, the phase is not specified and cannot be assumed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
"Tamoxifen for residual NF-PitNETs: A Proof-of-Concept study integrating receptor profiling, pilot trial, and target pathway analysis". PMID 40889098 · Endocrine · 2025-Nov The record describes a pilot randomized trial with a drug intervention and original results, but it is not a Phase III/IIIb or Phase II/III definitive trial, and its primary efficacy endpoint is radiographic tumor volume change at a fixed timepoint, not a time-to-event endpoint requiring Kaplan-Meier analysis or hazard ratio reporting.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials. PMID 40877636 · Br J Cancer · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Controlled Trial of Resection Versus Thermal Ablation of Colorectal Cancer Liver Metastases (New Comet): Study Protocol. PMID 40858956 · Ann Surg Oncol · 2025-Nov 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis. PMID 40856088 · Ann Clin Transl Neurol · 2025-Nov 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. PMID 40854410 · Ann Oncol · 2025-Nov The record describes a secondary, long-term, biomarker-focused analysis of the ECOG-ACRIN 3805 (CHAARTED) trial. While it presents OS results from a randomized, oncology trial with drug intervention, it is not the original primary report of the Phase III trial results but a secondary analysis exploring prognostic factors.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ipsilateral High Thoracic Ultrasound-Guided Erector Spinae Plane Block for Post-Thoracotomy Shoulder Pain in Thoracic Cancer Surgeries: A Randomized Controlled Clinical Trial. PMID 40841229 · J Cardiothorac Vasc Anesth · 2025-Nov The record describes a randomized controlled trial in thoracic cancer patients, but it lacks explicit Phase III classification, involves a non-drug intervention (nerve block), and does not include a time-to-event oncology efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Including comparative observational evidence in trial-level surrogate endpoint evaluation: assessing relapse-free survival as a surrogate endpoint for overall survival in patients with acute myeloid leukemia post-transplant. PMID 40825512 · J Clin Epidemiol · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer. PMID 40817986 · Breast Cancer Res Treat · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer. PMID 40781051 · Urol Oncol · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Letter to the Editor: Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open‑label, phase II/III study. PMID 40768025 · Gastric Cancer · 2025-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ultrasound-Guided Stellate Ganglion Block Regulates Inflammatory Cytokines and Improves Short-Term Outcome after Cardiac Surgery with Cardiopulmonary Bypass: A Randomized Clinical Trial. PMID 40764224 · J Cardiothorac Vasc Anesth · 2025-Nov The study is a randomized trial in cardiac surgery, not oncology. It evaluates an intervention (stellate ganglion block) for inflammatory cytokines and short-term outcomes after cardiac surgery. It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) and does not meet the oncology or efficacy endpoint criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial. PMID 40759832 · Breast Cancer Res Treat · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Laparoscopic ovarian drilling vs. step-up gonadotropin therapy in infertile anovulatory polycystic ovary syndrome women resistant to sequential letrozole and gonadotropin-based ovulation induction cycles: a randomized controlled trial. PMID 40759374 · F S Sci · 2025-Nov 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide. PMID 40742002 · BJU Int · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results. PMID 40738833 · Clin Lung Cancer · 2025-Nov The study is a Phase IIIb trial in oncology (ES-SCLC) with human subjects, a drug-containing intervention, and time-to-event efficacy endpoints (OS, PFS). However, it is explicitly described as a 'single-arm study' in the methods, which does not meet the requirement for randomization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study. PMID 40711960 · J Urol · 2025-Nov The trial is oncology-related, involves human patients with prostate cancer, is randomized, phase 3, includes a drug intervention (metformin), and reports original results. However, it is excluded because the primary efficacy endpoint is not a time-to-event outcome; it is a cross-sectional proportion at a fixed time point.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dietary Fiber Intake and Prostate Cancer Outcomes and All-Cause Mortality: Findings From a Secondary Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Study. PMID 40684909 · J Acad Nutr Diet · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial. PMID 40683357 · J Am Acad Dermatol · 2025-Nov The trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, the primary efficacy endpoint is treatment failure at 24 months (a binary outcome), not a time-to-event endpoint with survival analysis. No Kaplan-Meier curves, hazard ratios, or time-to-event data are reported.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931. PMID 40680992 · Ann Oncol · 2025-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Primary cardioprotective effect of sacubitril/valsartan in breast cancer patients receiving adjuvant therapy. PMID 40637120 · Eur J Heart Fail · 2025-Nov The study meets oncology, human, randomized, drug intervention, and original result criteria. However, it lacks a required time-to-event efficacy endpoint; the primary outcome is a binary categorical measure (CTRCD incidence) at 12 months, not a survival or time-to-event analysis. Therefore, it is excluded from the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. PMID 40582920 · Clin Lung Cancer · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Treatment Effect Estimation With Potential Outcomes for a Single-Arm Trial Compared With Historical Controls: A Case Study of Locally Recurrent Head and Neck Squamous Cell Carcinoma Patients Treated With Adjuvant Nivolumab. PMID 40525328 · Head Neck · 2025-Nov The record describes a single-arm trial analyzed with historical controls, not a randomized trial. It also appears to be a methodological study comparing statistical techniques rather than a primary report of a randomized Phase II/III or III trial with a drug intervention and time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer. PMID 40485075 · J Clin Pharmacol · 2025-Nov The study is an original report of a phase III randomized trial in oncology with a drug intervention, but it presents a cardiac safety analysis (QT prolongation) and does not report on a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the required time-to-event criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia. PMID 40413154 · Clin Lymphoma Myeloma Leuk · 2025-Nov The report is a safety analysis of cardiac events from three Phase 3 randomized trials. It does not report a primary or key secondary time-to-event efficacy endpoint required for inclusion.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term outcomes of prophylactic right-half dissection of the superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: five-year results from a randomized phase II trial. PMID 40380996 · Surg Today · 2025-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Barrett's Oesophagus Surveillance Versus Endoscopy at Need Study (BOSS): A Randomized Controlled Trial. PMID 40180292 · Gastroenterology · 2025-Nov The study is an oncology-related randomized trial with time-to-event endpoints and original results, but it does not meet the drug-intervention requirement, which is mandatory for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -